secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001528287-23-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q3 revenue $16.4M (+47% YoY), raises FY2023 guidance to $62.5-$63.5M
------------------------------------------------------------------------------

- Revenue $16.4M (+47% YoY); net loss $7.3M vs $11.8M a year ago.
- Cash burn reduced to $2.2M in Q3, down from $4M in Q2 and $9.8M in Q1.
- Full-year revenue guidance raised to $62.5-$63.5M (prev $59-$61M); gross margin guided 71%-73%.
- FDA approved Tablet Remote Monitor; launched nSight platform. NAUTILUS trial enrollment on track for Q1 2024.
- First RNS implants in community setting under Project CARE; sufficient cash to fund operations into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000040/0001528287-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000040/npce-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001528287-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer